156 related articles for article (PubMed ID: 38427117)
1. The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages.
Henning P; Westerlund A; Movérare-Skrtic S; Lindholm C; Márquez-Méndez M; Nilsson S; Holmberg AR; Lerner UH
Invest New Drugs; 2024 Apr; 42(2):207-220. PubMed ID: 38427117
[TBL] [Abstract][Full Text] [Related]
2. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.
Huang XL; Liu C; Shi XM; Cheng YT; Zhou Q; Li JP; Liao J
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34935053
[TBL] [Abstract][Full Text] [Related]
4. Aminothiazoles inhibit osteoclastogenesis and PGE
Kats A; Gerasimcik N; Näreoja T; Nederberg J; Grenlöv S; Lagnöhed E; Desai S; Andersson G; Yucel-Lindberg T
J Cell Mol Med; 2019 Feb; 23(2):1152-1163. PubMed ID: 30506812
[TBL] [Abstract][Full Text] [Related]
5. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
Idris AI; Landao-Bassonga E; Ralston SH
Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
[TBL] [Abstract][Full Text] [Related]
6. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
8. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of zoledronic acid derivatives with extended methylene linkers on osteoclastogenesis involve downregulation of JNK and Akt pathways.
Peng Y; Liu Q; Xu D; Li K; Li H; Qiu L; Lin J
Cell Biol Int; 2021 May; 45(5):1015-1029. PubMed ID: 33404170
[TBL] [Abstract][Full Text] [Related]
10. [Zoledronate regulates osteoclast differentiation and bone resorption in high glucose through p38 MAPK pathway].
Lin Y; Gu Y; Zuo G; Jia S; Liang Y; Qi M; Dong W
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1439-1447. PubMed ID: 33118518
[TBL] [Abstract][Full Text] [Related]
11. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
12. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
13. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
[TBL] [Abstract][Full Text] [Related]
14. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
15. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
16. Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling.
Koide M; Kinugawa S; Ninomiya T; Mizoguchi T; Yamashita T; Maeda K; Yasuda H; Kobayashi Y; Nakamura H; Takahashi N; Udagawa N
J Bone Miner Res; 2009 Aug; 24(8):1469-80. PubMed ID: 19292614
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effect of vitamin K on RANKL-induced osteoclast differentiation and bone resorption.
Wu WJ; Kim MS; Ahn BY
Food Funct; 2015 Oct; 6(10):3351-8. PubMed ID: 26267519
[TBL] [Abstract][Full Text] [Related]
18. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
19. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
20. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]